文献速递妇科

σ1受体在子宫颈癌中的过表达及其合成配体对子宫颈癌细胞生长的影响

[Clinical significance of σ1 receptor over-expression in cervical cancer and the effect of its synthetic ligands on the growth of cervical cancer cells].
PubMed 文献 · Zhonghua Fu Chan Ke Za Zhi · 2017-01-01

该研究检测了160份子宫颈病变组织中σ1R蛋白表达,并分析TCGA数据库中249例子宫颈癌患者数据,同时合成4种σ1R配体化合物作用于HeLa和SiHa细胞。结果显示σ1R在子宫颈癌和HSIL中过表达,其胞核表达与不良预后相关,化合物14a可抑制癌细胞增殖、迁移并增强奈达铂敏感性。

要点

  • σ1R蛋白在子宫颈癌和HSIL组织中过表达,胞核表达是子宫颈腺癌的重要特征。
  • σ1R阳性尤其胞核表达与子宫颈癌患者中位生存时间缩短相关。
  • 化合物14a可抑制HeLa和SiHa细胞增殖与迁移,并增强奈达铂的细胞毒性。

核心结论

  • σ1R在子宫颈癌和HSIL中过表达,其胞核表达是子宫颈腺癌的重要标志,σ1R过表达尤其胞核表达与子宫颈癌不良预后相关。
  • 新合成的σ1R配体化合物14a可抑制子宫颈癌细胞生长和迁移,通过诱导凋亡和阻滞细胞周期于G(0)/G(1)期发挥作用,并增强奈达铂诱导的细胞毒性。

研究设计与样本

  • 收集2007年1月至2012年12月郑州大学第二附属医院病理科存档的子宫颈病变组织蜡块160份,其中子宫颈癌88份、HSIL 42份、正常子宫颈30份,采用免疫组化SP法检测σ1R蛋白表达。
  • 从TCGA数据库筛选临床资料和σ1R基因数据完整的子宫颈癌患者249例,分析σ1R表达与临床病理特征的相关性。
  • 合成4种σ1R配体化合物14a、14e、15c、15f,作用于HPV18阳性HeLa细胞和HPV16阳性SiHa细胞,采用MTT法、划痕实验和流式细胞术检测增殖、迁移、细胞周期和凋亡。

主要发现

  • 子宫颈鳞癌σ1R表达显著高于HSIL或正常子宫颈组织,HSIL与正常组织间无显著差异;子宫颈腺癌σ1R表达高于鳞癌(P=0.020),腺癌胞核表达率10/18高于鳞癌27.1%(19/70;P=0.024)。
  • 70例鳞癌中47例σ1R阳性患者中位生存时间(45.8±3.1)个月低于23例阴性患者(51.7±2.9)个月(P=0.045);胞核阳性者(38.9±3.8)个月短于仅胞质表达者(48.7±2.1)个月(P=0.022)。
  • 18例腺癌中胞核阳性者中位生存时间(35.0±6.3)个月短于仅胞质表达者(44.2±4.2)个月(P=0.034)。
  • TCGA数据中208例鳞癌σ1R mRNA表达与年龄相关(P=0.005),与中位生存时间无显著相关(P=0.930);41例腺癌σ1R表达与临床分期、淋巴结转移、脉管浸润相关(均P<0.05),过表达者中位生存时间显著低于低表达者(P=0.034)。
  • 化合物14a(6 μmol/L)联合奈达铂48小时对HeLa和SiHa细胞的抑制率显著高于单用奈达铂(P<0.01);14a(30 μmol/L)作用24小时HeLa和SiHa迁移率分别为(19.6±0.6)%、(15.8±0.8)%,低于对照(43.0±1.2)%、(29.3±1.0)%(均P<0.01);14a(30 μmol/L)作用48小时HeLa和SiHa凋亡率分别为(16.3±1.1)%、(21.3±1.9)%,高于对照(1.8±0.3)%、(2.8±0.3)%(均P<0.01)。

关键数值与推荐

  • 子宫颈腺癌σ1R胞核表达阳性率10/18高于鳞癌27.1%(19/70),P=0.024。
  • 70例鳞癌σ1R阳性47例中位生存时间(45.8±3.1)个月低于阴性23例(51.7±2.9)个月,P=0.045。
  • 14a(30 μmol/L)作用24小时HeLa迁移率(19.6±0.6)%低于对照(43.0±1.2)%,SiHa(15.8±0.8)%低于对照(29.3±1.0)%,均P<0.01。
  • 14a(30 μmol/L)作用48小时HeLa凋亡率(16.3±1.1)%高于对照(1.8±0.3)%,SiHa(21.3±1.9)%高于对照(2.8±0.3)%,均P<0.01。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To explore the role of σ1 receptor (σ1R) in the clinical prognosis of cervical cancer,and provide a theoretical basis for σ1R targeted molecular therapy through observing the inhibition of synthetic σ1R-specific ligand compounds on the growth of cervical cancer cells. Methods: (1) Immunohistochemical or immunocytochemistry staining were respectively used to detect the expression and localization of σ1R protein. (2) The Cancer Genome Atlas (TCGA) data set was used to validate our results. (3) Two series of 4 novel σ1R ligand compounds were synthesized by altering the N-terminal substituents on the piperidine ring of the prezamicol analogue, named as 14a, 14e, 15c and 15f. Methyl thiazolyl-tetrazolium (MTT) assay was detect the anti-proliferative effect of the four compounds on HeLa and SiHa cells. Compound 14a with potent inhibitory activity and the highest specificity of σ1R was selected for further experiments. Scratch test was observed the migration effect of compound 14a on HeLa and SiHa cells. Flow cytometry was determined cell cycles and apoptosis. Results: (1) Immunostaining of σ1R protein was located in the cytoplasm and nucleus of cervical epithelium. The expression of cervical squamous cell carcinoma (SCC) was significantly higher than those of high-grade squamous intraepithelial lesion (HSIL) or normal cervical tissues. There was no significant difference in the expression of σ1R between HSIL and normal cervical tissues. σ1R expression in cervical adenocarcinoma (AC) was higher than that in SCC (P=0.020). The nuclear expression rate of σ1R in AC (10/18) was higher than that of SCC (27.1%, 19/70; P=0.024). The median overall survival (MOS) of σ1R-positive SCC patients was lower than that of σ1R-negative patients [(45.8±3.1) vs (51.7±2.9) months, P=0.045]. MOS of the patients with σ1R nuclear positive SCC was lower than that of non-nuclear staining [(38.9±3.8) vs (48.7±2.1) months, P=0.022]. MOS of the patients with σ1R nuclear positive AC was lower than that of non-nuclear staining [(35.0±6.3) vs (44.2±4.2) months, P=0.034]. (2) Analysis of TCGA data showed that σ1R expression of in SCC was correlated with age (P=0.005). σ1R expression in AC was significantly associated with advanced stage, lymphnode metastasis and vascular invasion (all P<0.05). MOS of AC patients with σ1R overexpression was significantly lower than that of the patients with low expression (P=0.034). There was no significant difference in the MOS of different expression of σ1R mRNA in SCC patients(P=0.930). (3) MTT assay showed that these four compounds could suppressed the growth of HeLa and SiHa cells in time- and dose-dependent manner. The growth inhibition rates of HeLa and SiHa cells at 48 hours treated by combination of different concentrations of nedaplatin (NDP) with compound 14a (6 μmol/L) were significantly higher than those treated by NDP alone. Compound 14a (30 μmol/L) significantly inhibited the migration (both P<0.01) and induced the apoptosis of HeLa or SiHa cells (both P<0.01). Conclusions: σ1R is over-expressed in cervical cancer and HSIL. σ1R nuclear expression is an important marker of AC. σ1R over-expression, especially σ1R nuclear expression is associated with the poor prognosis of cervical cancer. Our study is mostly consistent with cervical cancer data of TCGA. These results suggest that the novel synthetic prezamicol analogues 14a for σ1R could inhibit the growth of cervical cancer cells and cell migration through inducing apoptosis and arresting cell cycle in G(0)/G(1) period, enhance NDP-induced cytotoxicity. 目的: 探讨σ1受体(σ1R)在子宫颈癌组织中高表达的意义及其配体化合物对子宫颈癌细胞生长的作用。 方法: (1)收集2007年1月至2012年12月郑州大学第二附属医院病理科存档的经手术切除或活检的不同程度子宫颈病变组织蜡块160份,其中子宫颈癌组织88份、高级别鳞状上皮内病变(HSIL)组织42份、正常子宫颈组织30份(因子宫肌瘤、单纯良性卵巢囊肿行子宫全切除术);另选择HPV18型阳性的子宫颈腺癌细胞系HeLa细胞和HPV16型阳性的子宫颈鳞癌细胞系SiHa细胞。采用免疫组化SP法检测上述组织和细胞中σ1R蛋白的表达,并分析σ1R蛋白表达与子宫颈癌患者不同临床病理特征及预后的相关性。(2)从癌症基因组图谱(TCGA)数据库中筛选出临床资料和σ1R基因数据均完整的子宫颈癌患者249例,分析σ1R表达与子宫颈癌患者不同临床病理特征的相关性。(3)合成σ1R配体化合物(共4个,分别为化合物14a、14e、15c、15f)并作用于HeLa、SiHa细胞,采用四甲基偶氮唑蓝(MTT)比色法检测细胞增殖情况及细胞对奈达铂的敏感性,细胞划痕实验检测细胞迁移能力,流式细胞仪检测细胞周期比例和凋亡率。 结果: (1)免疫组化SP法检测显示,正常子宫颈组织中σ1R蛋白少量表达于胞质,HSIL组织中σ1R蛋白中等量表达于胞质及个别胞核,子宫颈癌组织中σ1R蛋白大量表达于胞质和胞核;子宫颈癌HeLa和SiHa细胞中σ1R蛋白大量表达于胞质和胞核。子宫颈癌患者σ1R蛋白的阳性表达率与病理类型明显相关(P=0.020),而与患者年龄、临床分期、病理分化程度均无明显相关性(P>0.05)。子宫颈腺癌患者σ1R蛋白的胞核表达阳性率(10/18)明显高于子宫颈鳞癌(27.1%,19/70;P=0.024)。70例子宫颈鳞癌患者中,47例σ1R蛋白阳性患者的中位生存时间[(45.8±3.1)个月]明显低于23例σ1R蛋白阴性表达患者[(51.7±2.9)个月;t=4.037,P=0.045];该47例患者中,15例为胞质表达伴胞核表达,32例仅胞质表达,中位生存时间前者明显短于后者[分别为(38.9±3.8)、(48.7±2.1)个月;t=5.239,P=0.022]。18例子宫颈腺癌患者中,10例为胞质表达伴胞核表达,8例仅胞质表达,中位生存时间前者也明显短于后者[分别为(35.0±6.3)、(44.2±4.2)个月;t=4.505,P=0.034]。(2)对TCGA数据库中筛选出的249例σ1R mRNA表达相关的子宫颈癌患者资料的分析显示,208例鳞癌患者中,σ1R mRNA表达与患者年龄明显相关(P=0.005);41例腺癌患者中,σ1R mRNA表达与临床分期、淋巴结转移、脉管浸润明显相关(P<0.05)。208例鳞癌患者中,σ1R mRNA表达与患者中位生存时间无明显相关性(P=0.930);而41例腺癌患者中,σ1R mRNA表达与中位生存时间明显相关(P=0.034)。(3)MTT比色法检测显示,4个化合物作用后对HeLa和SiHa细胞增殖均有抑制作用,并均呈明显的浓度依赖性(P<0.01);化合物14a(6 μmol/L)联合奈达铂作用于HeLa、SiHa细胞48 h后,其细胞增殖的抑制率明显高于单纯奈达铂作用后的细胞(P<0.01)。细胞划痕实验显示,化合物14a(30 μmol/L)作用24 h后,HeLa、SiHa细胞迁移率分别为(19.6±0.6)%、(15.8±0.8)%,均明显小于相应对照细胞[分别为(43.0±1.2)%、(29.3±1.0)%,P<0.01]。流式细胞仪检测显示,化合物14a(30 μmol/L)作用48 h后,HeLa、SiHa细胞的凋亡率[分别为(16.3±1.1)%、(21.3±1.9)%]均明显高于相应对照细胞[分别为(1.8±0.3)%、(2.8±0.3)%;P<0.01];HeLa、SiHa细胞的G(0)/G(1)期比例均明显高于相应对照细胞(P<0.05),HeLa细胞的S期比例无明显变化(P=0.948)、G(2)/M期比例显著降低(P=0.042),而SiHa细胞的S期比例显著降低(P=0.003)、G(2)/M期比例无明显变化(P=0.810)。 结论: σ1R蛋白在子宫颈癌和HSIL组织中呈过度表达,且σ1R蛋白的胞核表达是子宫颈腺癌的重要特征,σ1R蛋白阳性表达尤其是胞核表达与子宫颈癌患者的不良预后有关。新合成的σ1R配体化合物14a可显著抑制子宫颈癌HeLa和SiHa细胞的增殖,并提高细胞对奈达铂的敏感性,抑制细胞迁移能力,其可能通过诱导细胞凋亡和阻滞细胞周期而发挥抗肿瘤作用。.

来源:Zhonghua Fu Chan Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Deng YQ, Zhou XH, Jiang LL, et al. [Clinical significance of σ1 receptor over-expression in cervical cancer and the effect of its synthetic ligands on the growth of cervical cancer cells]. Zhonghua Fu Chan Ke Za Zhi. 2017. PMID: 28797155. doi:10.3760/cma.j.issn.0529-567X.2017.07.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。